tiprankstipranks
TipRanksTop Financial ExpertsInsidersEdward T Mathers

Edward T Mathers Insider Profile

11 Followers
Edward T Mathers, Director at OnKure Therapeutics, holds 15.31K shares in OnKure Therapeutics (Ticker: OKUR), holds ― shares in AKOUOS (Ticker: AKUS), holds 21.17K shares in Rhythm Pharmaceuticals (Ticker: RYTM).
See the Hottest Stocks Based on Insider Trading >
tipranks
Edward T Mathers

Edward T Mathers
OnKure Therapeutics (OKUR)
Director

Ranked #88,327 out of 108,921 Corporate Insiders

Profitable Transactions

43%
3 out of 7 Profitable Transactions

Average Return

-19.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
How are Insiders Ranked?

Insider Holdings

$670M
33.92%
24.76%
19.77%
16.36%
5.19% Others
A breakdown of Edward T Mathers's holdings
See the Top Stocks by Insiders

Insider Roles

MBX Biosciences, Inc.
(MBX)
Director
SpyGlass Pharma
(SGP)
Ten Percent Owner
Savara
(SVRA)
Ten Percent Owner
Monte Rosa Therapeutics
(GLUE)
Ten Percent Owner
+7 other positions
Roles that Edward T Mathers holds in companies
See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:
Savara
(SVRA)
Rating:Informative Buy
Date:Jul 19, 2023 - Jul 19, 2024
Return:+37.90%
The most profitable trade made by Edward T Mathers
See the Latest Stocks Traded by Insiders

Edward T Mathers's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
OKUR
OnKure Therapeutics
Jan 02, 2026
Director
Uninformative Buy
―
$51.75K
AKUS
AKOUOS
―
―
―
―
GLUE
Monte Rosa Therapeutics
Jun 30, 2021
Ten Percent Owner
Uninformative Buy
―
$109.69M
SNTI
Senti Biosciences
―
Director
―
―
NEUE
NeueHealth Inc
Oct 06, 2025
―
Informative Sell
24.54K
$0.00
SVRA
Savara
Jul 19, 2023
Ten Percent Owner
Informative Buy
1000.00K
$132.51M
KRRO
Korro Bio
Mar 12, 2026
Ten Percent Owner
Informative Buy
2.30M
$16.78M
MBX
MBX Biosciences, Inc.
Sep 17, 2024
Director
Informative Buy
8.00M
$227.39M
SGP
SpyGlass Pharma
Feb 11, 2026
Ten Percent Owner
Uninformative Buy
―
$165.96M
SYBX
Synlogic
―
Director
―
―
RYTM
Rhythm Pharmaceuticals
Mar 16, 2026
Director
Uninformative Buy
―
$2.14M
RARX
Ra Pharmaceuticals
―
―
―
―
TRVI
Trevi Therapeutics
Apr 13, 2022
Director
Uninformative Buy
1.80M
$15.79M
MIRM
Mirum Pharmaceuticals
―
Director
―
―
INZY
Inozyme Pharma
―
―
―
―
List of latest transactions for each holding click on a transaction to see Edward T Mathers's performance on stock
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Edward T Mathers insider profile FAQ

What is the percentage of profitable transactions made by Edward T Mathers?
The percentage of profitable transactions made by Edward T Mathers is 43%.
    What is the average return per transaction made by Edward T Mathers?
    The average return per transaction made by Edward T Mathers is -19.10%.
      What stocks does Edward T Mathers hold?
      Edward T Mathers holds: OKUR, AKUS, GLUE, SNTI, NEUE, SVRA, KRRO, MBX, SGP, SYBX, RYTM, RARX, TRVI, MIRM, INZY stocks.
        What was Edward T Mathers’s latest transaction?
        Edward T Mathers latest transaction was an Uninformative Buy of ―.
          What was Edward T Mathers's most profitable transaction?
          Edward T Mathers’s most profitable transaction was an Informative Buy of SVRA stock on July 19, 2023. The return on the trade was 37.90%.
            What is Edward T Mathers's role in OnKure Therapeutics?
            Edward T Mathers's role in OnKure Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.